1.Mermin, JH, et al. Typhoid fever in the United States, 1985–1994: changing risks of international travel and increasing antimicrobial resistance. Archives of Internal Medicine 1998; 158: 633–638.
2.Mirza, SH, Beeching, NJ, Hart, CA. Multi-drug resistant typhoid: a global problem. Journal of Medical Microbiology 1996; 44: 317–319.
3.Parry, CM, et al. Typhoid fever. New England Journal of Medicine 2002; 347: 1770–1782.
4.Wain, J, et al. Quinolone-resistant Salmonella typhi in Vietnam: molecular basis of resistance and clinical response to treatment. Clinical Infectious Diseases 1997; 25: 1404–1410.
5.National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, document M7-A6. National Committee for Clinical Laboratory Standards, Wayne, PA, 2004.
6.Bhan, MK, Bahl, R, Bhatnagar, S. Typhoid and paratyphoid fever. Lancet 2005; 366: 749–762.
7.Linh, NN, Arnold, K. Treatment of typhoid fever and typhoid carriers in Southeast Asia. Viewpoint from South Vietnam. Drugs 1975; 9: 241–243.
8.Parry, CM. The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Vietnam. Transactions of the Royal Society of Tropical Medicine and Hygiene 2004; 98: 413–422.
9.Sood, S, et al. Re-emergence of chloramphenicol-sensitive Salmonella typhi. Lancet 1999; 353: 1241–1242.
10.Umansanker, S, Wall, RA, Berger, J. A case of ciprofloxacin-resistant typhoid fever. Communicable Disease Review 1992; 2: R130–140.
11.Kadhiravan, T, et al. Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi. BMC Infectious Diseases 2005; 5: 37.
12.Parry, C, et al. Quinolone-resistant Salmonella typhi in Vietnam. Lancet 1998; 351: 1289.